7W3 Stock Chart & Stats
€1.47
€0.03(4.26%)
At close: 4:00 PM EST
€1.47
€0.03(4.26%)
Day’s Range― - ―
52-Week Range€0.60 - €1.59
Previous CloseN/A
Volume184.00
Average Volume (3M)0.00
Market Cap
€205.19M
Enterprise Value€3.25K
Total Cash (Recent Filing)€806.80M
Total Debt (Recent Filing)€193.70M
Price to Earnings (P/E)―
Beta0.59
Next Earnings
Mar 29, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding313,389,160
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)2.48
Price to Sales (P/S)5.68
P/FCF Ratio25.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.06
Revenue Forecast (FY)€81.82M
Bulls Say, Bears Say
Bulls Say
Improved ProfitabilityThe sharp improvement in net margin alongside higher revenue indicates stronger operating leverage and/or cost control. If maintained, this profitability provides more internal funding for product development, commercial expansion, and resilience across the next several quarters.
Strong Cash GenerationStrong operating and free cash flow means reported earnings are converting into usable funds, supporting investment without excessive external financing. This improves the company’s ability to fund innovation, sales expansion, and routine obligations through the medium term.
Conservative LeverageModest leverage and a larger equity base give Acotec greater financial flexibility than a highly indebted structure. Lower debt burden can reduce financing pressure and leave more capacity to absorb operating volatility or support expansion over coming quarters.
Bears Say
Historical Earnings VolatilityPast losses and uneven earnings show that the recent recovery has not yet been proven across a full operating cycle. Continued volatility could make planning, resource allocation, and investor confidence less dependable even after the 2025 improvement.
Inconsistent Cash ConversionAlthough 2025 cash generation was healthy, the prior negative years and latest year-over-year decline indicate that cash conversion remains inconsistent. This can constrain self-funded growth and make liquidity more dependent on sustained operating performance.
Margin Normalization And Moderate ReturnsThe decline from earlier exceptionally high gross margins suggests some profitability benefit may be normalizing rather than permanently expanding. Combined with only moderate ROE, this indicates that capital efficiency and margin durability still require continued improvement.
Acotec Scientific Holdings Limited News
7W3 FAQ
What was Acotec Scientific Holdings Limited’s price range in the past 12 months?
Acotec Scientific Holdings Limited lowest stock price was €0.60 and its highest was €1.59 in the past 12 months.
What is Acotec Scientific Holdings Limited’s market cap?
Acotec Scientific Holdings Limited’s market cap is €205.19M.
When is Acotec Scientific Holdings Limited’s upcoming earnings report date?
Acotec Scientific Holdings Limited’s upcoming earnings report date is Mar 29, 2027 which is in 190 days.
How were Acotec Scientific Holdings Limited’s earnings last quarter?
Acotec Scientific Holdings Limited released its earnings results on Aug 31, 2026. The company reported -€0.035 earnings per share for the quarter.
Is Acotec Scientific Holdings Limited overvalued?
According to Wall Street analysts Acotec Scientific Holdings Limited’s price is currently Overvalued.
Does Acotec Scientific Holdings Limited pay dividends?
Acotec Scientific Holdings Limited does not currently pay dividends.
What is Acotec Scientific Holdings Limited’s EPS estimate?
Acotec Scientific Holdings Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Acotec Scientific Holdings Limited have?
Acotec Scientific Holdings Limited has 313,389,160 shares outstanding.
What happened to Acotec Scientific Holdings Limited’s price movement after its last earnings report?
Acotec Scientific Holdings Limited reported an EPS of -€0.035 in its last earnings report. Following the earnings report the stock price went down -1.429%.
Which hedge fund is a major shareholder of Acotec Scientific Holdings Limited?
Currently, no hedge funds are holding shares in DE:7W3
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Acotec Scientific Holdings Limited
Acotec Scientific Holdings Limited is a medical technology firm specializing in the research and development of percutaneous transluminal angioplasty (PTA) and drug-coated balloon devices. These innovative products are designed to address various vascular diseases across Mainland China, Europe, and international markets. One key product, AcoArt Orchid & Dhalia, is developed to prevent the narrowing or blockage of superficial femoral and popliteal arteries, offering a treatment for lower extremity artery disease. This product is also currently undergoing clinical trials for additional applications, including arteriovenous fistula stenosis in nephrology, vertebral atherosclerotic stenosis in neurology, and vasculogenic erectile dysfunction in andrology. Another offering, AcoArt Tulip & Litos, is in the process of registration in China and Europe. Furthermore, it is under preclinical evaluation in the United States for treating below-the-knee artery disease within vascular surgery, and also for vasculogenic erectile dysfunction in andrology. The company was founded in 2020 and is headquartered in Beijing, China. Acotec Scientific Holdings Limited operates as a subsidiary of CA Medtech Investment (Cayman) Limited.
Technical Analysis
MicroPort Scientific
―
LifeTech Scientific Corporation
―
AK Medical Holdings Ltd.
―
MicroPort NeuroTech Limited
―
MicroTech Medical (Hangzhou) Co., Ltd. Class H
―